Table 2.
ACR testing rate at baseline*
| Research cohorts | General population clinical cohorts | Referred CKD clinical cohort | ||
|---|---|---|---|---|
| Diabetes | All | All | eGFR <60 ml/min/1.73 m2 | All |
| Number of cohorts | 6 | 24 | 24 | 1 |
| Number of participants | 38,753 | 1,303,027 | 241,247 | 2,814 |
| Proportion (%), mean (cohort range) | 94.2 (41.2–100) | 35.1 (12.3−74.5) | 36.9 (10.9–69.1) | 88.3 |
| Hypertension (without diabetes) | ||||
| Number of cohorts | 4 | 20 | 20 | 1 |
| Number of participants | 222,874 | 2,109,486 | 320,329 | 2101 |
| Proportion (%), mean (cohort range) | 97.0 (29.5–99.5) | 4.1 (1.3–20.7) | 6.2 (1.8−31.7) | 71.7 |
*
Baseline was defined as the first visit with ACR measurement in research cohorts and in a pre-selected two-year time window in clinical cohorts
ACR, urine albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate